Summary of Lifeward’s Q1 2025 Financial Performance
Lifeward Ltd. (NASDAQ: LFWD), a leader in innovative medical technology, has reported its financial results for the first quarter of 2025. Revenue reached $5.0 million, with strategic advancements aligning the company for future growth. Notably, there was a remarkable 42.2% gross margin achieved, significantly up from 26.4% compared to the previous year.
Key Highlights and Innovations
During the quarter, Lifeward launched the ReWalk 7 personal exoskeleton in the U.S. and secured its first insurance claim approval from a major commercial health insurer for the device. This marks an important milestone in expanding Lifeward's product coverage beyond Medicare.
Partnerships formed during this period were crucial; Lifeward teamed up with CorLife to increase distribution of the ReWalk system for those with workers’ compensation claims, while enhancing distribution rights for the MyoCycle FES system, which targets home applications. Such initiatives are designed to bolster the company's presence in key market segments.
Financial Overview
Revenue from the ReWalk Exoskeletons, MyoCycles, and ReStore Exo-Suits fell to $1.7 million, reflecting the impact of prior Medicare shipments that skewed previous year comparatives. However, revenue from AlterG products saw a 17% increase, totaling $3.3 million, primarily driven by increased international demand.
Operating expenses decreased to $7.0 million from $7.9 million, showcasing cost-saving initiatives implemented as a result of the closure of the Fremont location. As a result, the operating loss was reduced to $4.9 million, compared to a loss of $6.5 million for the same period last year.
Liquidity Position
At the end of the first quarter, Lifeward maintained $5.7 million in unrestricted cash and cash equivalents, without any debt obligations. Notably, the company anticipates a sequential decline in cash burn throughout the year as they manage their resources effectively.
Future Financial Outlook
Lifeward projects total revenue for 2025 to range between $28 million and $30 million, underscoring a positive growth trajectory fueled by ongoing product innovations and enhanced market accessibility.
Conference Call Information
Investors and interested parties are invited to join the upcoming conference call to discuss the financial results. Here are the details:
- Date: May 15, 2025
- Time: 8:30 AM EST
- U.S. Dial-in: 1-833-316-0561
- International Dial-in: 1-412-317-0690
About Lifeward Ltd.
Lifeward is dedicated to transforming the rehabilitation landscape for individuals with physical limitations and disabilities. With a mission that focuses on relentless innovation, Lifeward's product portfolio includes the ReWalk Exoskeleton and the AlterG Anti-Gravity system, among others. Founded in 2001, Lifeward has significant operations in multiple countries, instilling its commitment to improving lives through advanced medical technologies.
Frequently Asked Questions
What were Lifeward's revenues for Q1 2025?
Lifeward reported revenues of $5.0 million for Q1 2025.
How did the gross margin change compared to the previous year?
The gross margin increased to 42.2% in Q1 2025 from 26.4% in Q1 2024.
What are Lifeward's projections for 2025 revenues?
The company projects 2025 revenues to range between $28 million and $30 million.
What are Lifeward's major partnerships mentioned in the report?
Lifeward has established partnerships with CorLife for workers' compensation claims and expanded its rights with MYOLYN for home-use applications.
How much cash and equivalents does Lifeward have?
As of March 31, 2025, Lifeward had $5.7 million in unrestricted cash and cash equivalents.
